GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ImmunityBio Inc.
ImmunityBio is a biotechnology company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. Its stock price is highly volatile and depends on the results of clinical trials and FDA decisions regarding its drugs.
Share prices of companies in the market segment - Oncology immuno-therapy
ImmunityBio is a biotech company developing next-generation immunotherapies. We classify it as part of the immuno-oncology sector, and the chart below reflects the general trends and investor sentiment in this cutting-edge field of biotechnology.
Broad Market Index - GURU.Markets
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how ImmunityBio compares to it.
Change in the price of a company, segment, and market as a whole per day
IBRX - Daily change in the company's share price ImmunityBio Inc.
Shares of ImmunityBio, a company developing immunotherapy for cancer treatment, are experiencing extreme volatility. Change_co measures the market's reaction to news about clinical trials and FDA decisions. This metric is a critical component of System.GURU.Markets' formulas that evaluate binary risks in biotech.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
ImmunityBio, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with IBRX's performance, which hinges on the results of clinical trials of its immunotherapy platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
ImmunityBio is a biopharmaceutical company developing immunotherapies for the treatment of cancer and infectious diseases. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this field, helping to assess the risks and dynamics of ImmunityBio stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ImmunityBio Inc.
ImmunityBio is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
ImmunityBio, Inc. is a late-stage biotech company developing innovative immunotherapies for the treatment of cancer and infectious diseases. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ImmunityBio is a late-stage biotech whose fate hinges on the approval and success of its immunotherapeutic drugs. Its stock price is completely disconnected from economic cycles. Its chart is a history of binary events: positive regulatory news can trigger a surge, while failure can lead to a collapse.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ImmunityBio Inc.
The performance of ImmunityBio, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its immunotherapy drugs and regulatory decisions that impact its ability to bring new cancer treatments to market.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
ImmunityBio is a biotech company developing cutting-edge immunotherapies to combat cancer and infectious diseases. Its future depends entirely on the success of clinical trials. The biotech sector performance chart provides an indicator of investor appetite for risky innovation, providing context for assessing ImmunityBio's breakthrough potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ImmunityBio is a biotech company developing a new generation of immunotherapies for the treatment of cancer and infectious diseases. Its performance is completely unrelated to the market. Against the backdrop shown in the chart, ImmunityBio shares could rise or fall on FDA news or clinical trial data. It's a binary bet on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ImmunityBio Inc.
Shares of ImmunityBio, an oncology biotech, are experiencing extreme volatility. Weekly price movements are entirely dependent on news about clinical trials, FDA decisions, and scientific publications. The chart below is a clear example of how short-term events and investor expectations shape value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
How does ImmunityBio's performance compare to the broader biotech sector? This chart compares the company's weekly stock price movements, driven by news about its oncology platform, with the overall trend. This helps us understand whether the stock's movement is the result of a unique scientific event or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ImmunityBio is a biotech company developing cutting-edge immunotherapies for the treatment of cancer and infectious diseases. This chart shows how its weekly performance is detached from the market. Its share price movements are driven solely by news about clinical trials, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
IBRX - Market capitalization of the company ImmunityBio Inc.
The price chart of ImmunityBio, Inc. reflects the hopes for its innovative immunotherapy platform for treating cancer and infectious diseases. The company's market cap, led by a renowned billionaire surgeon, is heavily dependent on clinical trial results. Its performance reflects investors' faith in its scientific breakthrough.
IBRX - Share of the company's market capitalization ImmunityBio Inc. within the market segment - Oncology immuno-therapy
ImmunityBio, Inc. is a biotechnology company developing advanced immunotherapies for the treatment of cancer and infectious diseases. Its share of its sector market capitalization reflects the high potential of its scientific platform. The chart shows how investor expectations for its clinical developments and potential breakthroughs shape its market value.
Market capitalization of the market segment - Oncology immuno-therapy
The chart below reflects the pulse of the biotech sector focused on immuno-oncology. ImmunityBio, with its comprehensive approach to activating the immune system, is an ambitious player. The dynamics in the chart reflect the enormous hopes and risks associated with developing the next generation of cancer drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market valuation of a breakthrough in cancer immunotherapy. ImmunityBio's market capitalization reflects investors' faith in its innovative platform, which activates the body's immune system to fight tumors. The line illustrates how the hope of defeating cancer drives enormous value in global biotechnology.
Book value capitalization of the company, segment and market as a whole
IBRX - Book value capitalization of the company ImmunityBio Inc.
ImmunityBio, Inc.'s book value is a reflection of its scientific and production capital. The chart below reflects the valuation of its immunotherapy platform patents and its cell therapy manufacturing capabilities. Growth in the pipeline reflects investments in the development of breakthrough treatments for cancer and infectious diseases.
IBRX - Share of the company's book capitalization ImmunityBio Inc. within the market segment - Oncology immuno-therapy
ImmunityBio's resources include advanced manufacturing facilities and research centers for developing complex immunotherapeutic drugs. The chart shows the company's share of this high-tech physical infrastructure, which enables it to fully develop drugs for cancer and infectious diseases.
Market segment balance sheet capitalization - Oncology immuno-therapy
ImmunityBio is an immunotherapy company. Unlike many "soft" biotechs, it owns large manufacturing facilities, making it more capital-intensive. The graph will show whether this vertical integration (science and manufacturing) is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
ImmunityBio's balance sheet includes a comprehensive immuno-oncology development portfolio and manufacturing capabilities for vaccines and cell therapy. The company's assets represent capital invested in creating a comprehensive platform to combat cancer and infectious diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ImmunityBio Inc.
ImmunityBio is a biotech company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. It has no tangible assets. Its enormous market capitalization reflects investors' faith in the breakthrough potential of its scientific platform. Its price is a clear barometer of hopes for the victory over cancer.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
ImmunityBio is a biotech company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. Its valuation is based almost entirely on expectations for its scientific platform. The chart shows the wide gap between market valuation and book value, typical of disruptive biotechs.
Market to book capitalization ratio for the market as a whole
ImmunityBio is a biotech company developing next-generation immunotherapies for cancer and infectious diseases. The chart demonstrates the market's faith in this revolutionary approach to medicine. Its enormous market capitalization is not due to tangible assets, but rather reflects investors' bet that its platform will change the paradigm for treating serious diseases.
Debts of the company, segment and market as a whole
IBRX - Company debts ImmunityBio Inc.
ImmunityBio is a biopharmaceutical company working at the intersection of immunology and oncology. Developing complex cell therapies requires colossal investments in research, clinical trials, and manufacturing capacity. This chart shows how the company is raising significant capital to fund its mission to fight cancer.
Market segment debts - Oncology immuno-therapy
ImmunityBio is a late-stage biopharmaceutical company developing next-generation immunotherapies for cancer treatment. Their approach is aimed at activating the patient's own immune system. This chart shows the general financial metrics for the biotech sector, highlighting how the company is raising significant capital to bring its complex and breakthrough drugs to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ImmunityBio Inc.
ImmunityBio is a biotech company working at the intersection of immunology and oncology. Its goal is to teach the immune system to fight cancer. This is a cutting-edge, but extremely capital-intensive, field of science. This chart shows how the company funds its extensive and expensive clinical programs, primarily through equity capital.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. This chart compares the debt it raised to fund breakthrough but risky research with the total market capitalization of the entire oncology sector. It demonstrates the scale of its scientific ambitions and financial needs.
Debt to book value of all companies in the market
ImmunityBio is at the forefront of the fight against cancer. This chart compares its debt, taken on for breakthrough research, to the overall book value of the entire economy. It shows how large the company's financial stakes in science are in the context of the overall size of the stock market, which is the source of its capital.
P/E of the company, segment and market as a whole
P/E - ImmunityBio Inc.
This metric for ImmunityBio, Inc., a late-stage biopharmaceutical company in the field of immuno-oncology, reflects investor expectations. Its value is determined not by current profits, but by faith in its cancer-fighting platform. The chart shows how close the market is to recognizing its technologies as breakthroughs.
P/E of the market segment - Oncology immuno-therapy
This metric represents the average valuation for the biotech sector in which ImmunityBio operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
ImmunityBio is a late-stage biotech company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. The company aims to activate a patient's immune system. This risk appetite chart helps understand how investors evaluate potential breakthroughs in oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ImmunityBio Inc.
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. This chart reflects the high investor expectations for the success of its innovative platform, demonstrating the market's belief that the company's scientific developments will lead to medical breakthroughs.
%20P%2FE%20ImmunityBio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ImmunityBio-Inc.&v=1772490363347 "Chart of the company's future (projected) P/E ImmunityBio Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
ImmunityBio is an immunotherapy company in late-stage clinical development. It is developing a new generation of cell therapies and vaccines that activate a patient's immune system to fight cancer and infectious diseases. This chart shows overall market sentiment towards the biotech sector, helping to assess ImmunityBio's potential in oncology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772490363348 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
ImmunityBio is a biotech company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. Its valuation is a bet on a scientific breakthrough. It is completely uncorrelated with overall market forecasts and depends solely on the results of clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772490363350 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ImmunityBio Inc.
ImmunityBio is a late-stage biopharmaceutical company developing innovative immunotherapies for the treatment of cancer and infectious diseases. Its financial performance primarily reflects significant investments in clinical research and development. This chart shows the company's financial trajectory as it seeks to commercialize its cutting-edge scientific platform.
Profit of companies in the market segment - Oncology immuno-therapy
ImmunityBio, Inc. is a late-stage immunotherapy company focused on developing drugs and vaccines for the treatment of cancer and infectious diseases. This chart shows the profitability of the oncology sector. The company invests heavily in research, which impacts its current overall profitability, but its platform could lead to the development of a new generation of drugs.
Overall market profit
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapeutic drugs for the treatment of cancer and infectious diseases. Its value and future depend on scientific breakthroughs and the success of clinical trials. This chart illustrates general economic cycles, as ImmunityBio develops technologies that have the potential to transform medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ImmunityBio Inc.
ImmunityBio is a late-stage biopharmaceutical company focused on developing advanced immunotherapies for the treatment of cancer and infectious diseases. This chart reflects analysts' future earnings expectations, based on the potential of its innovative platform and the likelihood of approval of its key drug candidates.
%20profit%20of%20the%20company%20ImmunityBio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ImmunityBio-Inc.&v=1772490363360 "Graph of future (projected) profit of the company ImmunityBio Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
ImmunityBio, Inc. is a late-stage immunotherapy company developing next-generation cell therapies for the treatment of cancer and infectious diseases. This chart shows profitability projections for the oncology sector. It reflects high expectations for breakthroughs in immunotherapy that could radically change approaches to cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772490363361 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
ImmunityBio, Inc. is a biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. This cutting-edge science is capital-intensive. The overall profit forecast reflected here impacts the investment climate. A positive market environment facilitates the significant funding ImmunityBio needs for late-stage research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772490363362 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ImmunityBio Inc.
ImmunityBio, Inc. is a late-stage biopharmaceutical company developing immunotherapies for cancer. Following the recent approval of its first drug, P/S will become a key metric, reflecting investors' perception of the company's commercial launch and the potential of its oncology platform.
P/S market segment - Oncology immuno-therapy
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapeutic drugs for the treatment of cancer and infectious diseases. Their valuation is based on the potential of their platform. The chart shows how high investor expectations are for their science and future revenue, which is typical for companies at the forefront of the fight against cancer.
P/S of the market as a whole
ImmunityBio is a biotech company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. Revenue is currently minimal, and its market cap reflects hopes for a breakthrough in medicine. This chart, showing the estimated real revenue, emphasizes that ImmunityBio's valuation reflects an investment in science and long-term prospects.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ImmunityBio Inc.
ImmunityBio is a biotech company developing cutting-edge immunotherapies for the treatment of cancer and infectious diseases. Its valuation is a bet on its scientific platform. This chart represents the market's estimate of the future commercial potential of its complex cell therapies if they prove effective and are approved.
%20P%2FS%20ImmunityBio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ImmunityBio-Inc.&v=1772490363371 "The graph of the company's future (projected) P/S ImmunityBio Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
ImmunityBio, Inc. is a late-stage immunotherapy company developing next-generation treatments for cancer and infectious diseases. This chart shows how the market values the enormous future potential of its scientific platform compared to other oncology companies. Its valuation reflects high expectations for approval and commercial success of its drugs.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772490363374 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
ImmunityBio is a biotech company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. Its platform aims to activate the body's own immune system. This chart shows overall market revenue expectations, and ImmunityBio exemplifies how faith in scientific breakthroughs shapes long-term investment expectations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772490363377 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ImmunityBio Inc.
ImmunityBio, Inc. is a late-stage immunotherapy company developing next-generation cell therapies and vaccines for the treatment of cancer and infectious diseases. Its revenue is likely minimal or nonexistent in this graph, as its products are still in development. Future sales are dependent on the approval and commercial launch of its products.
Sales of companies in the market segment - Oncology immuno-therapy
ImmunityBio is a late-stage biotech developing immunotherapy for cancer. This chart shows revenue from its first approved drug. It allows investors to track the commercial launch and initial sales, a key milestone in the life of any biotech company.
Overall market sales
ImmunityBio, Inc. is a late-stage biopharmaceutical company developing immunotherapies for the treatment of cancer and infectious diseases. Its valuation is entirely dependent on the results of clinical trials and the potential of its scientific platform. The macroeconomic metrics reflected in this chart have no bearing on its mission to save lives.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ImmunityBio Inc.
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. Its revenue forecast is based on the expected commercial success of its approved drugs and progress in clinical trials. This chart demonstrates analysts' confidence in its innovative platform.
%20sales%20of%20the%20company%20ImmunityBio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ImmunityBio-Inc.&v=1772490363391 "Schedule of future (projected) sales of the company ImmunityBio Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. This chart displays projected revenue for the entire oncology immunotherapy segment. It provides insight into how rapidly analysts expect this cutting-edge market to grow, which is critical to ImmunityBio's future success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772490363394 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for cancer treatment. The company's success depends entirely on clinical trial results and regulatory approval. The overall economic situation, shown in the chart, does not affect demand but is critical for investor sentiment, which underpins the funding of expensive research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772490363397 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ImmunityBio Inc.
ImmunityBio is a biotech company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. This chart reflects the intensive research stage. It doesn't show profits, but rather the investment in developing breakthrough cell therapies, the success of which determines future profitability.
Market segment marginality - Oncology immuno-therapy
ImmunityBio is a biotechnology company developing cutting-edge immunotherapies for the treatment of cancer and infectious diseases. This indicator reflects the potential of its scientific platform. Future high profitability will be a testament to the clinical success of its developments and their potential to transform approaches to treating serious diseases.
Market marginality as a whole
ImmunityBio, Inc. is a late-stage immunotherapy company developing a new generation of cell therapies for cancer. Its future depends on regulatory approval. This chart shows the profitability of existing industries, while ImmunityBio aims to create a new paradigm in medicine, where the potential return on investment is enormous.
Employees in the company, segment and market as a whole
Number of employees in the company ImmunityBio Inc.
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for cancer treatment. The growth of its team of scientists and clinicians is directly related to the advancement of its platform and key candidates into late-stage clinical trials. This chart is an indicator of the intensity of its R&D activities.
Share of the company's employees ImmunityBio Inc. within the market segment - Oncology immuno-therapy
ImmunityBio is a late-stage biopharmaceutical company developing cutting-edge immunotherapeutic and cell therapies for the treatment of cancer and infectious diseases. This chart highlights its scientific potential. It reflects the proportion of leading immunologists, oncologists, and cell biologists working at the forefront of science that comprise this innovative company.
Number of employees in the market segment - Oncology immuno-therapy
ImmunityBio, Inc. is a late-stage immunotherapy company developing next-generation therapeutics to combat cancer and infectious diseases. This chart shows employment in the oncoimmunotherapy sector. The rapid growth of scientists in this field reflects the revolution in cancer treatment and the massive investment in activating the body's immune system.
Number of employees in the market as a whole
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. The growth of its scientific and clinical teams is a direct result of investments in breakthrough medical technologies. The company is at the forefront of science, where creating jobs equals creating hope.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ImmunityBio Inc. (IBRX)
ImmunityBio is a late-stage biotech company developing immunotherapies for cancer and infectious diseases. Their massive market cap reflects investors' bet on their scientific platform. This chart is a prime example of how the market values breakthrough scientific ideas: a small team of scientists creates potential value in the billions of dollars.
%20of%20the%20company%20ImmunityBio%20Inc.%20(IBRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ImmunityBio-Inc.-IBRX&v=1772490363417 "Chart of market capitalization per employee (in thousands of dollars) of the company ImmunityBio Inc. (IBRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
ImmunityBio is a late-stage biotech company that has received approval for its bladder cancer drug. Its value lies in its scientific R&D platform. This chart shows the industry average. It helps estimate the market value generated by this innovative immuno-oncology platform per scientist.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772490363418 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. The company's value reflects the hope for a scientific breakthrough. This chart reflects the enormous expectations of investors, with each scientist on the team seen as a bearer of potentially revolutionary knowledge.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772490363420 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ImmunityBio Inc. (IBRX)
ImmunityBio is a late-stage biotech company developing immunotherapies for cancer and infectious diseases. The company has an approved drug. This chart shows how well sales cover the company's significant R&D and personnel costs, and whether the company is starting to generate positive profits.
%20Chart%20ImmunityBio%20Inc.%20(IBRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ImmunityBio-Inc.-IBRX&v=1772490363421 "Company Profit Per Employee (in thousands of dollars) Chart ImmunityBio Inc. (IBRX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
ImmunityBio is a biotech company (immunotherapy) with an approved drug for bladder cancer. This chart shows the benchmark for the "Oncology" biotech sector. In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high (when a blockbuster drug is approved).
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772490363423 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
ImmunityBio is a biopharmaceutical company developing next-generation immunotherapies for cancer treatment. Their goal is to "teach" the patient's immune system to fight the disease. This is complex R&D. This chart, showing the average dollar return per employee across the market, begs the question: how does the immuno-oncology sector, where IBRX operates, compare to the norm?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772490363424 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ImmunityBio Inc. (IBRX)
ImmunityBio, Inc. is a late-stage biotech company focused on cancer immunotherapy. This chart reflects its progress toward commercialization. Prior to the recent drug approval, revenue per employee was low. It is now expected to grow sharply, demonstrating the financial potential of its scientific platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ImmunityBio-Inc.-IBRX&v=1772490363425 "Sales chart per company employee ImmunityBio Inc. (IBRX)")
Sales per employee in the market segment - Oncology immuno-therapy
ImmunityBio is a biotech company focused on immuno-oncology and recently received approval for its drug. This chart shows the average revenue per employee in the segment. It helps assess how productive the IBRX team is in commercializing its product compared to other biotechs already on the market.
Sales per employee for the market as a whole
ImmunityBio (IBRX) is a biotech company specializing in cancer immunotherapy. The company is on the verge of commercialization. Until recently, this metric was close to zero. Following the approval of their bladder cancer drug, this chart should show a sharp rise, reflecting the transition from 100% R&D to revenue generation.
Short shares by company, segment and market as a whole
Shares shorted by company ImmunityBio Inc. (IBRX)
ImmunityBio is a biotech company developing next-generation immunotherapies for cancer and infectious diseases. It's very ambitious. This chart shows extreme skepticism. The bears are betting that their complex cell therapies will be ineffective or too expensive for widespread use.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ImmunityBio-Inc.-IBRX&v=1772490363434 "Short Shares Chart for the Company ImmunityBio Inc. (IBRX)")
Shares shorted by market segment - Oncology immuno-therapy
ImmunityBio is a biotech company developing immunotherapies for the treatment of cancer and infectious diseases. This chart highlights the pessimism in the oncology sector. The rise in short positions across the sector reflects a general investor reluctance to take risks in companies with highly complex scientific platforms whose path to commercialization is long and extremely risky.
Shares shorted by the overall market
ImmunityBio (IBRX) is a late-stage biotech developing next-generation cell therapies and immunotherapies for cancer and infectious diseases. This chart measures overall market pessimism. For biotechs without stable profits, rising market fears represent a liquidity crisis. Investors flee risky ventures, making it harder for companies to fund expensive research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ImmunityBio Inc. (IBRX)
ImmunityBio is a clinical-stage biotech company focused on immuno-oncology. The stock is highly speculative. This chart can surge above 70 on positive R&D news or approvals. Oversold territory (<30) often reflects research setbacks or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ImmunityBio-Inc.-IBRX&v=1772490363440 "RSI 14 indicator chart for the company's stock ImmunityBio Inc. (IBRX)")
RSI 14 Market Segment - Oncology immuno-therapy
ImmunityBio is a clinical-stage biopharmaceutical company developing next-generation immunotherapies for the treatment of cancer and infectious diseases. Its approach is based on the activation of natural killer (NK) cells. This chart shows the overall "temperature" in the volatile immuno-oncology sector. It helps separate the dynamics of IBRX from the general hype or disillusionment in this field.
RSI 14 for the overall market
ImmunityBio (IBRX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IBRX (ImmunityBio Inc.)
ImmunityBio (IBRX) is a late-stage biopharmaceutical company developing immunotherapies (including NK cell-based ones) for the treatment of cancer and infectious diseases. The chart shows the average 12-month analyst forecast, reflecting their assessment of the likelihood of approval and commercial launch of the company's key bladder cancer drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IBRX-ImmunityBio-Inc.&v=1772490363448 "A chart showing analyst consensus forecasts for the expected stock price. IBRX (ImmunityBio Inc.)")
The difference between the consensus estimate and the actual stock price IBRX (ImmunityBio Inc.)
ImmunityBio is a late-stage biotech developing a new generation of immunotherapies for cancer treatment. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the consensus price forecast and the current price, reflecting confidence in their platform and drug approvals.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IBRX-ImmunityBio-Inc.&v=1772490363450 "A chart showing the difference between the consensus forecast and the actual stock price. IBRX (ImmunityBio Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
ImmunityBio (IBRX) is a biotech company at the forefront of R&D. It is developing an immunotherapy platform (including NK cells) to "train" the body to fight cancer. This chart shows analysts' overall expectations across the oncology sector, reflecting whether experts believe these complex R&D platforms will succeed.
Analysts' consensus forecast for the overall market share price
ImmunityBio (IBRX) is an R&D biotech focused on cancer immunotherapy (NK cell activation). They're burning through cash. This chart, reflecting expert expectations, is a measure of risk appetite for them. When the market is pessimistic, investors flee cash-burning biotechs whose returns are unclear.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ImmunityBio Inc.
ImmunityBio is a late-stage biotech company focused on immunotherapy for cancer treatment. Their goal is to awaken a patient's immune system to fight tumors. This chart is a clear indicator of biotech expectations. It likely reflects their clinical trial data, confidence in their scientific platform, and their recent success in gaining FDA approval.
AKIMA Market Segment Index - Oncology immuno-therapy
ImmunityBio (IBRX) is a biotech (owned by Dr. Patrick Soon-Shiong) focused on cancer immunotherapy; the company received approval for its first drug (Anktiva) for bladder cancer. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does IBRX's R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
ImmunityBio is a clinical-stage biotech company focused on cancer immunotherapy. Its platform attempts to activate a patient's own immune system to fight tumors. This is a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop for funding such companies.
